Skip to Main Content

News

Pretzel Therapeutics Receives UK Regulatory Authorization to Advance PX578 Into Clinical Development in Patients for the Treatment of POLG-Mediated Primary Mitochondrial Disorders

October 30, 2026

Pretzel Therapeutics Receives FDA Fast Track Designation for PX578 for the Treatment of POLG-mediated Primary Mitochondrial Disorders

September 22, 2026

Pretzel Therapeutics Advances PX578 into Phase 2 Study in Individuals Living with POLG-mediated Primary Mitochondrial Disease Following FDA Clearance of IND

August 25, 2026

Pretzel Therapeutics Presents Preclinical Data on PX578 at MDA 2026, Further Supporting Clinical Advancement in Individuals Living with POLG Disease

Pretzel Therapeutics Presents Preclinical Data Supporting POLRMT as a Novel Target for the Treatment of Metabolic Disease at ObesityWeek 2025

November 4, 2025

Pretzel Therapeutics Strengthens Leadership with Appointment of Ashish Dugar, Ph.D., MBA as Chief Development Officer

September 3, 2025

View Full Archive

Press
Releases

View Full Archive

Scientists just discovered a single molecule that may treat rare, devastating mitochondrial diseases

LiveScience • May 1, 2025

Small Molecule Restores Mitochondrial Function in POLG Disorders

Technology Networks • April 11, 2025

Pretzel Therapeutic Reveals Novel mtDNA Deficiency Syndrome Drugs

Inside Precision Medicine • April 10, 2025

Small molecule rescues unstable mitochondrial enzyme

C&ENews • April 10, 2025

Pretzel Therapeutics narrows the therapeutic gap for PolG disease

BioWorld • April 10, 2025

Pretzel advances mitochondrial therapy with PX578 Phase 1 trial

Parkinson’s News Daily • October 8, 2025

News